Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

2017392 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 389, Issue 10084, pp. 2117-2127

Field-Weighted Citation Impact: 18.22